Strategy for leukemia therapy

Details Strategy for leukemia therapy Strategy for leukemia therapy

2007-07-03

2007-07-03

Rawlings, Stephen L. (Department: 1643)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S194000, C435S372100, C514S252140, C514S252180, C514S253010

Reexamination Certificate

active

10312918

ABSTRACT:
The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.

REFERENCES:
Raanani et al. (Acta Haematol. 2005; 113 (3): 181-189).
Gura (Science. 1997; 278: 1041-1042).
Dan et al. (Cell Death Differ. Aug. 1998; 5 (8): 710-715).
Nagar et al. (Cancer Res. Aug. 1, 2002; 62 (15): 4236-4243).
Alefantis et al. (J. Biol. Chem. Jun. 13, 2003; 278 (24): 21814-21822).
Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Castro-Alcaraz (J. Immunol. 2002; 169: 3947-3953).
Deininger et al. (Blood. Nov. 15, 2000; 96 (10): 3343-3356).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Ferrari et al. (Clin. Exp. Immunol. 2003; 132: 1-8).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1 (1): 122-134).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Verma et al. (Nature 1997, 389: 239-242).
Patterson AP. Memorandum (Jan. 14, 2003); pp. 3.
Waller et al. (Anticancer Res. Mar.-Apr. 2000; 20 (2A): 809-814).
Wang (Oncogene. Nov. 20, 2000; 19: 5643-5650).
Huang et al. (Oncogene. 2002; 21: 8804-8816).
Wiseniewski et al. (Cancer Res. Aug. 1, 2002; 62: 4244-4255).
Beran, M. et al. Selective Inhibition of Cell Proliferation and BCR-ABL Phosphorylation in Acute Lymphoblastic Leukemia Cells ExpressingM, 190,000 BCR-ABL Protein by a Tyrosine Kinase Inhibitor (CGP-57148). Clinical Cancer Research, vol. 4, 1998, 1661-1672.
Cornetta, K. et al. Retroviral mediated gene transfer in chronic myelogenous leukaemia. British Journal of Haematology, 87, 1994, 308-316.
Deininger, M. et al. The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL-Positive Cells. Blood, vol. 90, No. 9, 1997, 3691-3698.
Dorsey, J. et al. The Pyrido[2,3-d]pyrimidine Derivative PD180970 Inhibits p210Bcr-AblTyrosine Kinase and Induces Apoptosis of K562 Leukemia Cells. Cancer Research 60,2000, 3127-3131.
Issaad, C. et al. Retro virus-mediated BCR-ABL (P210) gene transfer into the pluripotent human hematopoietic cell line UT-7 induces growth factor-independence and erythroid differentiation-bcr-abl oncogene gene transfer results in growth factor independence and erythroid differentiation; application in antisense gene transfer and cancer therapy (abstract). Blood, 84, 10, suppl. 1, 138a, 1994, 537.
Komiyama, K. et al. Antitumor Activity of Leptomycin B. The Journal of Antibiotics, vol. XXXVIII, No. 3, 1985, 427-429.
Marley, S. et al. The tyrosine kinase inhibitor ST1571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Experimental Hematology, 28, 2000, 551-557.
Melo, J. Inviting leukemic cells to waltz with the devil. Nature Medicine. vol. 7, No. 2, 2001, 156-157.
Smart, P. et al. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene, 18, 1999, 7378-7386.
Vigneri, P. et al. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Medicine, vol. 7, No. 2, 2001, 228-234.
Waller, C. et al. Growth Inhibition of Ph+Progenitor Cells from CML Patients Using the Tyrosine Kinase Inhibitor CGP57148B. Anticancer Research, 20, 2000, 809-814.

Affiliated with

Also associated with

Rating

Strategy for leukemia therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Strategy for leukemia therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Strategy for leukemia therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3784695